Altimmune (ALT) AI Stock Analysis

• Market Cap: $561.26M
• Dividend Yield: N/A
• Average Volume (3M): 2.84M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.20
• Revenue Growth: -95.12%
• EPS Growth: 21.09%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 81,106,970
• 10 Day Avg. Volume: 4,096,560
• 30 Day Avg. Volume: 2,842,158
• PEG Ratio: 0.41
• Price to Book (P/B): 4.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.31
• Enterprise Value/Market Cap: 1.18
• Enterprise Value/Revenue: 1.32K
• Enterprise Value/Gross Profit: -16.15K
• Enterprise Value/Ebitda: -1.67
• 1Y Price Target: $20.83
• Price Target Upside: 201.01% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 58 Neutral
• Price Target: $7.50 ▲(8.38%Upside)

Altimmune's stock score is primarily driven by strong earnings call guidance and technical momentum, despite challenging financial performance and valuation metrics. The company's strong balance sheet provides a cushion for future growth, but achieving profitability remains a significant hurdle.

Positive Factors

Clinical Results

Pemvidutide is showing rapid reductions in liver fat and improvement in cardiovascular risk, which are critical factors for success in treating liver-related conditions.

Regulatory Progress

Management confirmed that the Phase 3 FDA briefing package is already complete and that Altimmune expects to meet with the agency in early 4Q25, supporting potential initiation of a registrational program in early 2026.

Strategic Opportunities

The potential for Pemvidutide to outperform current treatments could drive strategic interest and collaboration opportunities.

Negative Factors

Clinical Trials

If successful, pemvidutide would become the first therapy in any class to demonstrate statistically significant improvements in both MASH resolution and fibrosis after just 24 weeks, while also delivering clinically meaningful weight loss.

Market Valuation

ALT currently seems undervalued trading at a discount to current Phase 3 MASH companies, presenting a significant opportunity to catch up in valuation.

Altimmune Business Overview & Revenue Model

Company Description

Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in the areas of liver disease and immune modulating therapies. The company is headquartered in Gaithersburg, Maryland, and is actively working on a pipeline that includes treatments for non-alcoholic steatohepatitis (NASH), obesity, and infectious diseases. Altimmune leverages its proprietary technologies to develop vaccines and therapies that aim to improve patient outcomes.

How the Company Makes Money

Altimmune primarily makes money through the development and commercialization of its proprietary drug candidates. The company's revenue streams consist of research and development collaborations, government contracts, and potential future product sales. Altimmune has previously received funding through government contracts for its infectious disease programs and may enter into partnerships with other pharmaceutical companies to co-develop or license its therapies. These partnerships can provide milestone payments and royalties, contributing to the company's revenue. Additionally, as its drug candidates progress through clinical trials, Altimmune may secure additional funding through equity offerings to support its operations and research initiatives.

Altimmune Financial Statement Overview

Summary

Altimmune's financial performance is challenged by inconsistent revenue and negative net income, indicating operational difficulties. However, its strong equity position and low leverage provide some financial stability.

Income Statement

Altimmune has shown inconsistent revenue figures over the years, with a significant drop in the most recent period. Gross profit margins have been volatile, and the company has consistently posted negative net income, leading to negative net profit margins. The EBIT and EBITDA margins are also negative, indicating operational challenges in achieving profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 88.65% in the latest period, reflecting a solid balance sheet with minimal debt. The debt-to-equity ratio is favorable, indicating low financial leverage. However, the persistent net income losses have impacted the return on equity, which remains negative.

Cash Flow

Altimmune has experienced negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, as is the free cash flow to net income ratio, reflecting the company's difficulties in translating earnings into cash flow.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
20.00K	20.00K	426.00K	-68.00K	4.41M	8.19M
	Gross Profit
-41.00K	20.00K	-51.00K	-568.00K	3.86M	-25.32M
	EBIT
-98.19M	-103.17M	-95.93M	-87.74M	-96.91M	-54.80M
	EBITDA
-90.75M	-94.81M	-87.94M	-84.40M	-96.53M	-54.15M
	Net Income Common Stockholders
-90.24M	-95.06M	-88.45M	-84.71M	-97.09M	-49.04M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
149.83M	131.89M	197.81M	184.88M	190.30M	215.92M
	Total Assets
157.26M	139.31M	210.64M	206.93M	218.86M	245.12M
	Total Debt
0.00	1.68M	671.00K	1.12M	1.53M	1.82M
	Net Debt
-49.10M	-35.24M	-134.45M	-109.97M	-188.77M	-114.09M
	Total Liabilities
15.10M	15.80M	16.54M	21.64M	19.73M	19.24M
	Stockholders Equity
142.16M	123.51M	194.10M	185.29M	199.13M	225.88M
Cash Flow		Free Cash Flow
-80.33M	-79.85M	-75.86M	-62.71M	-90.55M	-34.65M
	Operating Cash Flow
-80.33M	-79.85M	-75.81M	-62.59M	-78.24M	-34.44M
	Investing Cash Flow
6.03M	-28.39M	13.73M	-73.40M	87.52M	-72.09M
	Financing Cash Flow
44.42M	10.04M	86.11M	56.78M	65.10M	213.49M

Altimmune Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.92
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALT, the sentiment is Positive. The current price of 6.92 is above the 20-day moving average (MA) of 5.83, above the 50-day MA of 5.31, and above the 200-day MA of 6.55, indicating a bullish trend. The MACD of 0.34 indicates Negative momentum. The RSI at 66.84 is Neutral, neither overbought nor oversold. The STOCH value of 77.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALT.

Altimmune Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	78 Outperform	$629.50M	14.66	20.50%	―	2333.50%	―
ALT	58 Neutral	$561.26M	―	-57.28%	―	-95.12%	21.09%
AUTL	55 Neutral	$564.22M	―	-49.97%	―	-14.16%	25.80%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
IVA	51 Neutral	$469.73M	―	344.74%	―	-47.32%	-26.67%
ORIC	43 Neutral	$820.71M	―	-48.45%	―	―	7.15%
SANA	33 Underperform	$584.19M	―	-71.44%	―	―	19.94%

Altimmune Corporate Events

Altimmune Secures $100 Million Credit Facility

On May 13, 2025, Altimmune entered into a Loan and Security Agreement with Hercules Capital, securing a $100 million credit facility to enhance its financial flexibility and support the development of its lead therapeutic candidate, pemvidutide. The company announced its first quarter 2025 financial results, reporting cash and short-term investments of $150 million as of March 31, 2025. Altimmune anticipates significant milestones in 2025, including top-line data from the IMPACT Phase 2b trial of pemvidutide in MASH, and the initiation of Phase 2 trials for AUD and ALD. These developments are expected to strengthen Altimmune’s position in the biopharmaceutical industry, particularly in addressing unmet medical needs in liver and cardiometabolic diseases.

The most recent analyst rating on (ALT) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.